Tourmaline is a late-stage clinical biotechnology company driven by our mission to develop transformative medicines that dramatically improve the lives of patients with life-altering immune and inflammatory diseases. In doing so, we seek to develop medicines that have the potential to establish new standards-of-care in areas of high unmet medical need.

Contact information

Email: info@tourmalinebio.com
Or visit https://tourmalinebio.com

Clinical Trials

Randomized, double-masked, placebo-controlled study to investigate the efficacy and safety of TOUR006 (pacibekitug) in adults with TED

Intervention:
TOUR006 (pacibekitug), a fully human monoclonal antibody against IL-6L
Delivery – subcutaneous injection

Total Number of injections – 3
Time between injections – 8 weeks

Recruiting – 81 participants
NCT Number: NCT06088979
Study Name: spiriTED

Visit: https://clinicaltrials.gov/study/NCT06088979 for more information.

To help TED patients better understand your work and build meaningful connection, please consider responding to the following five questions.

1. What is your company’s focus when it comes to helping people living with TED and when did you start working in the TED space?

At Tourmaline Bio, our mission is to develop transformative medicines that address serious unmet needs in immune-mediated diseases, including Thyroid Eye Disease (TED). We entered the TED space with the goal of offering a differentiated approach that has the potential to improve both patient outcomes and treatment experience. Our work in TED began in 2023, leveraging our deep scientific expertise in targeting the underlying drivers of inflammation and tissue remodeling. We are committed to advancing therapies that can make a meaningful difference in the lives of people living with TED.

2. What is the therapeutic approach for your investigational or currently approved treatment?

Our lead investigational therapy for TED, TOUR001, is a high-affinity, anti-IGF-1R monoclonal antibody designed for subcutaneous (under the skin) administration. Unlike currently available therapies, which may require intravenous infusions, our approach aims to offer a convenient, patient-friendly treatment option. By targeting IGF-1R, a key pathway involved in TED, our goal is to reduce inflammation and prevent tissue expansion that leads to the characteristic symptoms of TED.

3. What symptoms are you measuring the impact of the investigational treatment on in your clinical trials? What has been observed so far in these trials, both from an efficacy and safety side?

In our clinical trials, we are evaluating TOUR001’s impact on proptosis (eye bulging), inflammatory signs (clinical activity score), diplopia (double vision), and quality of life.

4. Where can people go to learn more about your clinical trials and how can people find out if they are eligible to participate?

Patients and healthcare providers can learn more about our ongoing clinical trials at www.clinicaltrials.gov by searching for “TOUR001” or “Tourmaline Bio TED trials”. Additionally, we regularly update our website at www.tourmalinebio.com with study information. We encourage patients to speak with their healthcare providers about clinical trial opportunities, and we are actively working to broaden awareness through advocacy groups and community channels to make participation more accessible.

5. How do patients’ voices and experiences influence your research and product development?

At Tourmaline Bio, patients are at the heart of everything we do. From the earliest stages of clinical trial design to how we think about product delivery and real-world impact, we actively seek out patient and caregiver perspectives. We collaborate with patient advocacy groups to ensure we understand the challenges faced by those living with TED. This feedback informs how we design our studies, select meaningful endpoints, and develop treatment options that can better serve the diverse needs of the TED community. Our commitment is to listen, learn, and act—so we can improve the lives of people affected by TED.